|
|
| [PMID]: | 24675587 |
| [Au] Autor: | Thapa DR; Hussain SK; Tran WC; Dʼsouza G; Bream JH; Achenback CJ; Ayyavoo V; Detels R; Martínez-Maza O |
| [Ad] Dirección: | *University of California, Los Angeles, AIDS Institute, Los Angeles, CA; Departments of †Obstetrics and Gynecology; ‡Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; §Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA; ‖Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA; Departments of ¶Epidemiology; #Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; **Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; and ††Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA. |
| [Ti] Título: | Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. |
| [So] Fuente: | J Acquir Immune Defic Syndr;66(2):229-37, 2014 Jun 1. | | [Is] ISSN: | 1944-7884 |
| [Cp] País de publicación: | United States |
| [La] Idioma: | eng |
| [Ab] Resumen: | OBJECTIVE: To determine if changes in levels of serum microRNAs (miRNAs) were seen preceding the diagnosis of AIDS-related non-Hodgkin lymphoma (AIDS-NHL). DESIGN: Serum miRNA levels were compared in 3 subject groups from the Multicenter AIDS Cohort Study: HIV-negative men (n = 43), HIV-positive men who did not develop NHL (n = 45), and HIV-positive men before AIDS-NHL diagnosis (n = 62, median time before diagnosis, 8.8 months). METHODS: A total of 175 serum-enriched miRNAs were initially screened to identify differentially expressed miRNAs among these groups and the results validated by quantitative polymerase chain reaction. Receiver-operating characteristic analysis was then performed to assess biomarker utility. RESULTS: Higher levels of miR-21 and miR-122, and a lower level of miR-223, were able to discriminate HIV-infected from the HIV-uninfected groups, suggesting that these miRNAs are biomarkers for HIV infection but are not AIDS-NHL specific. Among the HIV-infected groups, a higher level of miR-222 was able to discriminate diffuse large B-cell lymphoma (DLBCL) and primary central nervous system lymphoma (PCNSL) subjects from HIV-infected subjects who did not develop NHL, with area under the receiver-operating characteristic curve of 0.777 and 0.792, respectively. At miR-222 cutoff values of 0.105 for DLBCL and 0.109 for PCNSL, the sensitivity and specificity were 75% and 77%, and 80% and 82%, respectively. CONCLUSIONS: Altered serum levels of miR-21, miR-122, and miR-223 are seen in HIV-infected individuals. Higher serum level of miR-222 has clear potential as a serum biomarker for earlier detection of DLBCL and PCNSL among HIV-infected individuals. |
| [Mh] Términos MeSH primario: |
Infecciones por VIH/diagnóstico
Linfoma Relacionado con SIDA/diagnóstico
MicroARNs/sangre
Marcadores Biológicos de Tumor/sangre
|
| [Mh] Términos MeSH secundario: |
Adulto
Anciano
Recuento de Linfocito CD4
Infecciones por VIH/sangre
Humanos
Linfoma Relacionado con SIDA/sangre
Linfoma de Células B Grandes Difuso/sangre
Linfoma de Células B Grandes Difuso/diagnóstico
Linfoma no Hodgkin/sangre
Linfoma no Hodgkin/diagnóstico
Masculino
Mediana Edad
Estudios Prospectivos
Curva ROC
Reacción en Cadena en Tiempo Real de la Polimerasa
Reproducibilidad de Resultados
Adulto Joven
|
| [Pt] Tipo de publicación: | JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL |
[Nm] Nombre de substancia:
| 0 (MicroRNAs); 0 (Tumor Markers, Biological) |
| [Em] Mes de ingreso: | 1407 |
| [Cu] Fecha actualización por clase: | 140714 |
| [Lr] Fecha última revisión: | 140714 |
| [Sb] Subgrupo de revista: | IM; X |
| [Da] Fecha de ingreso para procesamiento: | 140514 |
| [St] Status: | MEDLINE |
| [do] DOI: | 10.1097/QAI.0000000000000146 |
|
